A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy Clinical Trial

Official title:

A Multicentre, Randomised, Double-blind, Placebo-controlled and Open Label Extension Study to Assess the Efficacy, Safety, and Pharmacokinetic Profile of of ATL1102 in Non-ambulatory Participants With Duchenne Muscular Dystrophy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05938023
• Other study ID #: 1102-DMD-Pre-CT03
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 18, 2023
• Est. completion date: March 5, 2025

Study information

• Verified date: May 2024
• Source: Percheron Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase IIb study is a two part, multicenter study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of ATL1102 in non-ambulant boys with Duchenne Muscular Dystrophy aged 10 to <18 years old. The study includes a randomised, double-blind, placebo-controlled treatment period (Part A), followed by an open labelled treatment period (Part B).

Description:

This Phase IIb study is a two part, multicenter study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of ATL1102 and will enroll 45 non-ambulant boys with Duchenne Muscular Dystrophy (DMD) aged 10 to <18 years old.

During the 24 week randomised, double-blind, placebo-controlled treatment period (Part A) participants will be enrolled and randomised to receive either ATL1102 25mg, ATL1102 50mg or matched placebo in a 1:1:1 ratio given as a weekly subcutaneous injection.

Participants will then continue to the 24 week Open Labelled Treatment Period (Part B) and continue to receive ATL1102 25mg or ATL1102 50mg for a further 24 weeks. Participants on placebo in Part A will transition to ATL1102.

The study will consist of a 4 week screening period, 24 week randomised, double-blind, placebo-controlled treatment period (Part A), 24 week open label treatment period (Part B) and 16 week follow up period.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 48
• Est. completion date: March 5, 2025
• Est. primary completion date: November 13, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 10 Years to 17 Years

Eligibility

Key Inclusion Criteria:

• Has a clinical diagnosis of DMD confirmed by validated genetic testing

• Is considered to be non-ambulatory, defined as unable to walk 10 meters without assistance or help at Screening.

• Male aged 10 to less than 18 years, at the time of Screening.

• Body weight of at least 25 kg at Screening.

• If receiving corticosteroid therapy, therapy was initiated at least six months prior to the baseline visit and a stable daily dose for at least 3 months prior to baseline

• Participant has a Performance of Upper Limb Module for DMD 2.0 (PUL 2.0) Entry Item A score =2.

• Able to perform spirometry and has sufficient Respiratory function defined as reproducible percent predicted FVC =50%.

• Has adequate cardiac function defined as left ventricular ejection fraction (LVEF) =45% by echocardiogram and if receiving cardiac medication, must be currently on a stable regimen and doses of cardiac therapy (at least 3 months prior to baseline Day 1)

• Participant and their parent/guardian/carer are willing and able to comply with scheduled visits, study medication administration and study procedures.

Key Exclusion Criteria:

• Participation in another clinical trial (non-interventional) or administration of any investigational product or experimental product within 12 weeks or 5 half-lives (whichever is longer) preceding Day 1.

• Exposure to more than 3 investigational products within the 12 months prior to Day 1.

• History of clinically significant bleeding or coagulation abnormalities or clinically significant abnormal coagulation parameters.

• Currently receiving antiplatelet or anticoagulant therapy or has taken medication with an antiplatelet or anticoagulant effect within 4 weeks prior Day 1

• Any evidence of clinically significant structural or functional heart abnormality (cardiomyopathy that is managed by ACEi or beta blockers is acceptable provided the LVEF inclusion criterion is met).

• Known history of or a positive test for hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibodies, human immunodeficiency virus (HIV) antibodies at Screening.

• Evidence of renal impairment and/or cystatin C >1.4 mg/L.

• Received a live vaccine (including intranasal influenza vaccine) within 4 weeks prior to Day 1 or planned live vaccination during the study period.

• Asthma (if requiring regular medication), bronchitis/chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, pneumonia or the presence of any non-DMD respiratory illness that affects PEF and FVC or other respiratory measures.

• Requires day-time assisted mechanical or non-invasive ventilation (NIV) (night time NIV is permitted).

• Chronic use (daily intake >14 days), within one month of Day 1, of beta-2 agonists or any use of other bronchodilating medication (e.g., inhaled steroids, sympathomimetics, anticholinergics).

• Used carnitine, creatine, glutamine, oxatomide, idebenone or other forms of coenzyme Q10 or vitamin E or any other nutritional or antioxidant supplements or herbal medicines or anabolic steroids other than standard corticosteroids or puberty testosterone supplementation within 4 weeks of Day 1.

• Has an increased risk for opportunistic infections or systemic medical conditions resulting in significantly compromised immune system function

Related Conditions & MeSH terms

• Duchenne Muscular Dystrophy
• Muscular Dystrophies
• Muscular Dystrophy, Duchenne

Intervention

Drug:
• ATL1102 25mg
Dose and scheduled as specified in the Arm description
• ATL1102 50mg
Dose and scheduled as specified in the Arm description
• Placebo
Dose and scheduled as specified in the Arm description

Locations

Country	Name	City	State
Australia	Royal Childrens Hospital	Melbourne
Australia	Queensland Children's Hospital	South Brisbane
Australia	The Children's Hospital at Westmead	Westmead
Bulgaria	UMHAT Aleksandrovska Neurology clinic	Sofia
Serbia	Mother and Child Health Care Institute	Belgrade
Serbia	University Children's Hospital	Belgrade
Turkey	Eskisehir Osmangazi Universitesi Tip Fakultesi	Eskisehir
Turkey	Yeditepe University Hospital	Istanbul
Turkey	Marmara University Pendik Training and Research Hospital	Pendik
United Kingdom	Birmingham Heartlands Hospital	Birmingham
United Kingdom	The General Infirmary at Leeds, Leeds Teaching Hospital NHS Trust	Leeds
United Kingdom	University College London (UCL) - Great Ormond Street Institute of Child Health (ICH)	London
United Kingdom	The Robert Jones and Agnes Hunt Orthopaedic Hospital	Oswestry

Sponsors (1)

Lead Sponsor	Collaborator
Percheron Therapeutics

Countries where clinical trial is conducted

Australia,  Bulgaria,  Serbia,  Turkey,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in lymphocyte populations to assess pharmacodynamic effects of ATL1102 from baseline to Week 57	Lymphocyte population (cells/L) including cells expressing CD49d will be evaluated at multiple timepoints during the study utilizing chip cytometry.	57 weeks
Primary	Change in the Performance of Upper Limb (PUL) 2.0 score from baseline to Week 25 (blinded treatment period).	The PUL is an assessment used to evaluate the upper limb strength for individuals with DMD where a higher score indicates a better outcome with a minimum of 0 and a maximum score of 42	25 weeks
Primary	Change in the Performance of Upper Limb (PUL) 2.0 score from Week 25 to Week 49 (open label treatment period).	The PUL is an assessment used to evaluate the upper limb strength for individuals with DMD where a higher score indicates a better outcome with a minimum of 0 and a maximum score of 42	49 weeks
Primary	Change in the Performance of Upper Limb (PUL) 2.0 score from baseline to Week 49 (combined treatment period).	The PUL is an assessment used to evaluate the upper limb strength for individuals with DMD where a higher score indicates a better outcome with a minimum of 0 and a maximum score of 42	49 weeks
Primary	Safety measured by the incidence and frequency of adverse events, serious adverse events and suspected unexpected adverse events from baseline to Week 65	An Adverse Event is any untoward medical occurrence in a participant and does not necessarily have to have a causal relationship with the intervention.	65 weeks
Secondary	Change in the grip strength of the hand from baseline to Week 25 using a handheld dynamometer tool (MyoGrip) (blinded treatment period).	The handheld dynamometer tool (MyoGrip) use strain gauge technology to measure the hand strength in Kilograms exerted by the participants with higher recordings indicating greater hand strength.	25 weeks
Secondary	Change in the pinch strength of the fingers from baseline to Week 25 using handheld dynamometer tool (MyoPinch) (blinded treatment period).	The handheld dynamometer tool (MyoPinch) use strain gauge technology to measure the pinch strength of the fingers in Kilograms exerted by the participants with higher recordings indicating greater hand strength.	25 weeks
Secondary	Change in the respiratory function assessed by Forced Vital Capacity (FVC) from baseline to Week 25 (blinded treatment period).	The percent predicted for Forced Vital Capacity (FVC%p) will be calculated at multiple timepoints after respiratory function is assessed using spirometry tests	25 weeks
Secondary	Change in the respiratory function assessed by peak expiratory flow (PEF) from baseline to Week 25 (blinded treatment period).	The percent predicted for peak expiratory flow (PEF%p) will be calculated at multiple timepoints after respiratory function is assessed using spirometry tests	25 weeks
Secondary	Change in the Paediatric Quality of Life (PedsQL™) questionnaire Duchenne Muscular Dystrophy (DMD) Module from baseline to Week 25 (blinded treatment period).	Health related quality of life is assessed by percentage of change in the score collected in the Paediatric Quality of Life (PedsQL™) Duchenne Muscular Dystrophy (DMD) Module for participants and parents at multiple timepoints. A higher score indicates a better health related quality of life with a minimum of 0 and a maximum score of 100.	25 weeks
Secondary	Safety measured by the incidence and frequency of adverse events, serious adverse events and suspected unexpected adverse events from baseline to Week 25 (blinded treatment period).	An Adverse Event is any untoward medical occurrence in a participant and does not necessarily have to have a causal relationship with the intervention.	25 weeks
Secondary	Maximum and minimum plasma concentration (Cmax and Cmin) for ATL1102 over multiple timepoints	Pharmacokinetic evaluation to evaluate dose response	65 weeks
Secondary	Area under the plasma concentration time curve (AUC) for ATL1102 over multiple timepoints	Pharmacokinetic evaluation to evaluate dose concentration over time	65 weeks
Secondary	Time to Cmax and Cmin for ATL1102 over multiple timepoints	Pharmacokinetic evaluation to evaluate concentration of ATL1102	65 weeks
Secondary	The terminal half life for ATL1102	Pharmacokinetic evaluation to evaluate the time for the ATL1102 concentration to reduce by half	65 weeks
Secondary	Change in the grip strength of the hand from Week 25 to Week 49 using a handheld dynamometer tool (MyoGrip) (open label treatment period).	The handheld dynamometer tool (MyoGrip) use strain gauge technology to measure the hand strength in Kilograms exerted by the participants with higher recordings indicating greater hand strength.	49 weeks
Secondary	Change in the pinch strength of the fingers from Week 25 to Week 49 using handheld dynamometer tool (MyoPinch) (open label treatment period).	The handheld dynamometer tool (MyoPinch) use strain gauge technology to measure the pinch strength of the fingers in Kilograms exerted by the participants with higher recordings indicating greater hand strength.	49 weeks
Secondary	Change in the respiratory function assessed by Forced Vital Capacity (FVC) from Week 25 to Week 49 (open label treatment period).	The percent predicted for Forced Vital Capacity (FVC%p) will be calculated at multiple timepoints after respiratory function is assessed using spirometry tests	49 weeks
Secondary	Change in the respiratory function assessed by peak expiratory flow (PEF) from Week 25 to Week 49 (open label treatment period).	The percent predicted for peak expiratory flow (PEF%p) will be calculated at multiple timepoints after respiratory function is assessed using spirometry tests	49 weeks
Secondary	Change in the Paediatric Quality of Life (PedsQL) questionnaire Duchenne Muscular Dystrophy (DMD) Module from Week 25 to Week 49 (open label treatment period).	Health related quality of life is assessed by percentage of change in the score collected in the Paediatric Quality of Life (PedsQL™) Duchenne Muscular Dystrophy (DMD) Module for participants and parents at multiple timepoints. A higher score indicates a better health related quality of life with a minimum of 0 and a maximum score of 100.	49 weeks
Secondary	Change in the grip strength of the hand from baseline to Week 49 using a handheld dynamometer tool (MyoGrip) (combined treatment period).	The handheld dynamometer tool (MyoGrip) use strain gauge technology to measure the hand strength in Kilograms exerted by the participants with higher recordings indicating greater hand strength.	49 weeks
Secondary	Change in the pinch strength of the fingers from Baseline to Week 49 using handheld dynamometer tool (MyoPinch) (combined treatment period).	The handheld dynamometer tool (MyoPinch) use strain gauge technology to measure the pinch strength of the fingers in Kilograms exerted by the participants with higher recordings indicating greater hand strength.	49 weeks
Secondary	Change in the respiratory function assessed by Forced Vital Capacity (FVC) from Baseline to Week 49 (combined treatment period).	The percent predicted for Forced Vital Capacity (FVC%p) will be calculated at multiple timepoints after respiratory function is assessed using spirometry tests	49 weeks
Secondary	Change in the respiratory function assessed by peak expiratory flow (PEF) from baseline to Week 49 (combined treatment period).	The percent predicted for peak expiratory flow (PEF%p) will be calculated at multiple timepoints after respiratory function is assessed using spirometry tests	49 weeks
Secondary	Change in the Paediatric Quality of Life (PedsQL) questionnaire Duchenne Muscular Dystrophy (DMD) Module from Baseline to Week 49 (combined treatment period).	Health related quality of life is assessed by percentage of change in the score collected in the Paediatric Quality of Life (PedsQL™) Duchenne Muscular Dystrophy (DMD) Module for participants and parents at multiple timepoints. A higher score indicates a better health related quality of life with a minimum of 0 and a maximum score of 100.	49 weeks